Evotec AG - Articles and news items

Sembragiline fails to meet primary endpoint in Phase IIb trial in Alzheimer’s disease

Industry news / 2 July 2015 / Victoria White

Evotec and Roche have provided an update on the initial results of the Phase IIb trial with Sembragiline for the treatment of Alzheimer’s disease…


Evotec receives milestone as part of its multi-target alliance with Bayer HealthCare

Industry news / 13 October 2014 / Evotec

Evotec AG announced that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis…


Evotec and Roche to develop compound that could slow the progression of Alzheimer’s disease

Industry news, News / 6 September 2011 / Evotec AG

Evotec’s MAO-B inhibitor in patients with Alzheimer’s disease (AD) to be developed…

Roche logo

Roche and Evotec to jointly develop biomarkers in oncology

Industry news, News / 24 June 2011 / Roche

Roche and Evotec AG announced a collaboration in novel protein-activity based biomarkers for Roche’s oncology drugs…


Twelfth milestone payment as part of its discovery alliance with Boehringer Ingelheim received

Industry news, News / 9 May 2011 / Evotec AG

Twelfth milestone triggers payment of EUR 2 million to Evotec…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...